Mazdutide
aka IBI362
Mechanism
Mazdutide is a dual GLP-1 / glucagon receptor agonist licensed from Eli Lilly to Innovent Biologics for Greater China. Approved by China's NMPA in June 2025 for chronic weight management and in September 2025 for glycemic control in type 2 diabetes; NOT FDA-approved in the US.
Identification
| CAS number | 2259884-03-0 |
|---|---|
| Molecular formula | C207H317N45O65 |
| Typical dose | 2–10 mg subcutaneous once weekly (escalating regimen; approved maintenance doses in China 4.5–9 mg/week) |
| Half-life | ~5–7 days (clinical PK: t1/2 range 174.8–1075.7 h across doses) |
Vendors selling Mazdutide
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Skye Peptides | 6 mg | $99.00 | — | 90 |
| Peptidology | 10 mg | $79.99 | — | 89 |
| Cocer Peptides | 10 mg | $260.00 | — | 82 |
| Certified Peptides | 10 mg | $128.00 | — | 61 |
| Peptiatlas | — | — | — | 51 |
| zztai Peptide Ltd | 5 mg | $135.00 | — | 43 |
| zztai Peptide Ltd | 10 mg | $231.00 | — | 43 |
| Kimera Chems | — | $111.99 | — | — |
| Welli Labs | — | $79.99 | — | — |
| AMC Essentials | 6 mg | $89.99 | — | — |
| Flawless Compounds | — | — | — | — |
| Genetic Peptide | 5 mg | $100.00 | — | — |
| Genetic Peptide | 10 mg | $100.00 | — | — |
| Genetic Peptide | 15 mg | $100.00 | — | — |
| Genetic Peptide | 30 mg | $100.00 | — | — |
| Genetic Peptide | 60 mg | $100.00 | — | — |
| Polaris Peptides | 6 mg | $100.00 | — | — |
| Solution Peptides | 6 mg | $80.00 | — | — |
| Southern Aminos | 10 mg | $72.80 | — | — |
| optimasupply.is | 6 mg | $450.00 | — | — |
| realpeptides.co | — | $160.00 | — | — |
Research
Aim To assess the effects of mazdutide on body weight, HbA1c, metabolic outcomes, and adverse events in adults with overweight/obesity and/or type 2 diabetes (T2D).
source →Importance Obesity is a worldwide problem and a major public health issue in China. Objective To evaluate the efficacy and safety of mazdutide (a once-weekly glucagon and glucagon-like peptide-1 receptor dual agonist) in Chinese adults with obesity (defined as a body mass index of ≥30).
source →Adolescent obesity is an escalating global health concern associated with increased risks of cardiovascular disease, type 2 diabetes mellitus, and long-term metabolic complications.
source →Introduction Mazdutide is a dual glucagon-like peptide-1 receptor (GLP-1 R) and glucagon receptor (GCGR) agonist representing a new generation of incretin-based therapeutics for obesity and type 2 diabetes.
source →Background: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most prevalent chronic liver disorder globally. Mazdutide has shown clinical benefits in weight management and metabolic regulation, indicating its potential as a therapeutic agent for MASLD.
source →Background Once-weekly dual glucagon and glucagon-like peptide-1 receptor agonist mazdutide, administered at 4 and 6 mg, provides substantial weight loss in Chinese adults with overweight or obesity. This trial aimed to evaluate the efficacy and safety of mazdutide 9 mg in Chinese adults with obesity.
source →Introduction Glucagon receptor agonists (GRAs) are an emerging class of therapies for obesity and type 2 diabetes, demonstrating encouraging metabolic and weight-reducing effects.
source →Background Mazdutide, a dual GLP-1 and glucagon receptor agonist, shows promise for weight loss and glycaemic control. This study evaluates its efficacy in non-diabetic patients with obesity.
source →Objective To conduct a systematic, multi-dimensional clinical evaluation of five long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs) available in China, providing evidence-based guidance for clinical preference and institutional formulary selection.
source →Despite advances in type 2 diabetes (T2D) management, unmet needs remain for therapies that effectively control hyperglycaemia while addressing comorbid metabolic disorders 1,2 .
source →A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in participants with mild to moderate hypertension complicated by overweight/obesity who have not received antihypertensive drug treatment
source →The study is a first-in-pediatric assessment of the safety, tolerability, and pharmacokinetic characteristics of multiple doses of IBI362 in Chinese adolescent subjects with obesity. It employs a multicenter, randomized, double-blind, and placebo-controlled trial design.
source →This trial is conducted in China. The aim of the trial is to evaluate efficacy and Safety of IBI362 Versus dulaglutide as add-on to Metformin and/or SGLT2 inhibitor or TZD in Subjects With Type 2 Diabetes.
source →The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with Mazdutide compared with placebo and in adult participants with obesity or overweight. The study will last about 62 weeks.
source →The purpose of this study is to assess how fast IBI362 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
source →The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs).
source →This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of IBI362 in overweight or obese subjects. Subjects will be randomly assigned to IBI362 low-dose, high-dose and placebo groups.
source →This trial is conducted in China. The aim of this trial is to investigate Safety, Tolerability, PK and PD for Multiple Doses of IBI362 in Overweight or Obese Male and Female Subjects.
source →